Literature DB >> 27494916

HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection.

Martina Kovarova1, Uma Shanmugasundaram1, Caroline E Baker1, Rae Ann Spagnuolo1, Chandrav De1, Christopher C Nixon1, Angela Wahl2, J Victor Garcia1.   

Abstract

BACKGROUND: Approximately 1.5 million HIV-positive women become pregnant annually. Without treatment, up to 45% will transmit HIV to their infants, primarily through breastfeeding. These numbers highlight that HIV acquisition is a major health concern for women and children globally. They also emphasize the urgent need for novel approaches to prevent HIV acquisition that are safe, effective and convenient to use by women and children in places where they are most needed.
METHODS: 4'-Ethynyl-2-fluoro-2'-deoxyadenosine, a potent NRTI with low cytotoxicity, was administered orally to NOD/SCID/γc-/- mice and to bone marrow/liver/thymus (BLT) humanized mice, a preclinical model of HIV infection. HIV inhibitory activity in serum, cervicovaginal secretions and saliva was evaluated 4 h after administration. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine's ability to prevent vaginal and oral HIV transmission was evaluated using highly relevant transmitted/founder viruses in BLT mice.
RESULTS: Strong HIV inhibitory activity in serum, cervicovaginal secretions and saliva obtained from animals after a single oral dose of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (10 mg/kg) demonstrated efficient drug penetration into relevant mucosal sites. A single daily oral dose of 4'-ethynyl-2-fluoro-2'-deoxyadenosine resulted in efficient prevention of vaginal and oral HIV transmission after multiple high-dose exposures to transmitted/founder viruses in BLT humanized mice.
CONCLUSIONS: Our data demonstrated that 4'-ethynyl-2-fluoro-2'-deoxyadenosine efficiently prevents both vaginal and oral HIV transmission. Together with 4'-ethynyl-2-fluoro-2'-deoxyadenosine's relatively low toxicity and high potency against drug-resistant HIV strains, these data support further clinical development of 4'-ethynyl-2-fluoro-2'-deoxyadenosine as a potential pre-exposure prophylaxis agent to prevent HIV transmission in women and their infants.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27494916      PMCID: PMC5079298          DOI: 10.1093/jac/dkw283

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  41 in total

1.  Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.

Authors:  Michael W Melkus; Jacob D Estes; Angela Padgett-Thomas; Joel Gatlin; Paul W Denton; Florence A Othieno; Anja K Wege; Ashley T Haase; J Victor Garcia
Journal:  Nat Med       Date:  2006-10-22       Impact factor: 53.440

2.  2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma.

Authors:  Hiroshi Ohrui; Satoru Kohgo; Hiroyuki Hayakawa; Eiichi Kodama; Masao Matsuoka; Tomohiro Nakata; Hiroaki Mitsuya
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2007       Impact factor: 1.381

3.  Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1.

Authors:  Susan H Eshleman; Donald R Hoover; Sarah E Hudelson; Shu Chen; Susan A Fiscus; Estelle Piwowar-Manning; J Brooks Jackson; Newton I Kumwenda; Taha E Taha
Journal:  J Infect Dis       Date:  2006-01-11       Impact factor: 5.226

4.  2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.

Authors:  Atsushi Kawamoto; Eiichi Kodama; Stefan G Sarafianos; Yasuko Sakagami; Satoru Kohgo; Kenji Kitano; Noriyuki Ashida; Yuko Iwai; Hiroyuki Hayakawa; Hirotomo Nakata; Hiroaki Mitsuya; Eddy Arnold; Masao Matsuoka
Journal:  Int J Biochem Cell Biol       Date:  2008-04-11       Impact factor: 5.085

5.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

Authors:  Brandon F Keele; Elena E Giorgi; Jesus F Salazar-Gonzalez; Julie M Decker; Kimmy T Pham; Maria G Salazar; Chuanxi Sun; Truman Grayson; Shuyi Wang; Hui Li; Xiping Wei; Chunlai Jiang; Jennifer L Kirchherr; Feng Gao; Jeffery A Anderson; Li-Hua Ping; Ronald Swanstrom; Georgia D Tomaras; William A Blattner; Paul A Goepfert; J Michael Kilby; Michael S Saag; Eric L Delwart; Michael P Busch; Myron S Cohen; David C Montefiori; Barton F Haynes; Brian Gaschen; Gayathri S Athreya; Ha Y Lee; Natasha Wood; Cathal Seoighe; Alan S Perelson; Tanmoy Bhattacharya; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

6.  Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding.

Authors:  Maria Cristina Marazzi; Karin Nielsen-Saines; Ersilia Buonomo; Paola Scarcella; Paola Germano; Nuria Abdul Majid; Ines Zimba; Susanna Ceffa; Leonardo Palombi
Journal:  Pediatr Infect Dis J       Date:  2009-06       Impact factor: 2.129

7.  Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Authors:  Hirotomo Nakata; Masayuki Amano; Yasuhiro Koh; Eiichi Kodama; Guangwei Yang; Christopher M Bailey; Satoru Kohgo; Hiroyuki Hayakawa; Masao Matsuoka; Karen S Anderson; Yung-Chi Cheng; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

8.  Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1.

Authors:  Zhifeng Sun; Paul W Denton; Jacob D Estes; Florence A Othieno; Bangdong L Wei; Anja K Wege; Michael W Melkus; Angela Padgett-Thomas; Mary Zupancic; Ashley T Haase; J Victor Garcia
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

9.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Authors:  Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

10.  Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.

Authors:  Paul W Denton; Jacob D Estes; Zhifeng Sun; Florence A Othieno; Bangdong L Wei; Anja K Wege; Daniel A Powell; Deborah Payne; Ashley T Haase; J Victor Garcia
Journal:  PLoS Med       Date:  2008-01-15       Impact factor: 11.069

View more
  5 in total

1.  HIV co-infection augments EBV-induced tumorigenesis in vivo.

Authors:  Christopher B Whitehurst; Monica Rizk; Adonay Teklezghi; Rae Ann Spagnuolo; Joseph S Pagano; Angela Wahl
Journal:  Front Virol       Date:  2022-03-11

2.  Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.

Authors:  Angela Wahl; Phong T Ho; Paul W Denton; Katy L Garrett; Michael G Hudgens; Glenn Swartz; Cynthia O'Neill; Fulvia Veronese; Angela D Kashuba; J Victor Garcia
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

Review 3.  A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective.

Authors:  Jennifer L Bailey; Suzanne T Molino; Ana D Vega; Melissa Badowski
Journal:  Infect Dis Ther       Date:  2017-06-09

Review 4.  Moving beyond the mousetrap: current and emerging humanized mouse and rat models for investigating prevention and cure strategies against HIV infection and associated pathologies.

Authors:  Yash Agarwal; Cole Beatty; Shivkumar Biradar; Isabella Castronova; Sara Ho; Kevin Melody; Moses Turkle Bility
Journal:  Retrovirology       Date:  2020-04-10       Impact factor: 4.602

5.  M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.

Authors:  Maureen Oliveira; Bluma G Brenner; Hongtao Xu; Ruxandra-Ilinca Ibanescu; Thibault Mesplède; Mark A Wainberg
Journal:  J Antimicrob Chemother       Date:  2017-11-01       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.